Pain Practice · 2016 · 70 citations · 14 references
NursingPharmacologyPharmacotherapyGastrointestinal PharmacotherapyPain ManagementPain MedicineAnalgesiaConstipation ManagementConstipation PharmacotherapyOpioid AnalgesicsOpioid PharmacologyOpioid TherapyAnalgesic Efficacy AssessmentChronic Noncancer PainDaily DosingNoncancer Pain Opioid TherapyOpioid Antagonist TherapyOpioid-induced Constipation ManagementOpioid-induced Constipation TreatmentPeripherally Acting Opioid Receptor Antagonists
BACKGROUND: Subcutaneous methylnaltrexone, a peripherally acting μ-opioid receptor antagonist, improves opioid-induced constipation (OIC) in patients with chronic noncancer pain. An oral methylnaltrexone formulation has been developed. METHODS: In this phase 3, double-blind trial, adults with chronic noncancer pain receiving opioid doses of ≥ 50 mg/day oral morphine equivalents with OIC were randomly assigned to oral methylnaltrexone (150, 300, or 450 mg) or placebo once daily (QD) for 4 weeks followed by as-needed dosing for 8 weeks. Patients who had ≥ 3 rescue-free bowel movements (RFBMs)/week, with an increase of ≥ 1 RFBM/week from baseline for ≥ 3 of 4 weeks during the QD period, were responders. RESULTS: Overall, 803 patients were included in the analyses. A significantly greater percentage of patients had an increase in mean percentage of dosing days resulting in an RFBM within 4 hours of dosing during weeks 1 through 4 (QD period; primary endpoint) with methylnaltrexone (300 mg/day [24.6%; P = 0.002] and 450 mg/day [27.4%; P < 0.0001]) vs. placebo (18.2%). The percentage of responders (49.3% for 300 mg [P = 0.03] and 51.5% for 450 mg [P = 0.005] vs. 38.3% with placebo) and change from baseline in mean number of weekly RFBMs (difference vs. placebo, 0.5 for 300 mg [P = 0.03] and 0.5 for 450 mg [P = 0.02]) was significantly greater with methylnaltrexone 300 and 450 mg/day vs. placebo during the QD period. All dosages of oral methylnaltrexone were well tolerated. CONCLUSIONS: Oral methylnaltrexone was efficacious and well tolerated for OIC in patients with chronic noncancer pain, particularly the 450-mg dose.
14
Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain
Roger Chou, Gilbert J. Fanciullo, Perry G. Fine et al. · Journal of Pain · 2009 · 2.2K citations · Full text
Methylnaltrexone for Reversal of Constipation Due to Chronic Methadone Use
Chun‐Su Yuan, Joseph Foss, Michael O’Connor et al. · JAMA · 2000 · 298 citations
Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.
Neal E. Slatkin, Arthur G. Lipman, George Wilson et al. · PubMed · 2009 · 161 citations